Literature DB >> 9069593

Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

H Bocquet1, M Bagot, J C Roujeau.   

Abstract

Since the first description by Saltzstein in 1959, the denomination of drug-induced pseudolymphoma was used to describe two cutaneous adverse drug reactions with a histological picture mimicking malignant lymphoma. On the basis of clinical presentation, this term includes two different patterns: (1) hypersensitivity syndrome which begins acutely in the first 2 months after the initiation of the drug and associates fever, a severe skin disease with characteristic infiltrated papules and facial edema or an exfoliative dermatitis, lymphadenopathy, hematologic abnormalities (hypereosinophilia, atypical lymphocytes) and organ involvement such as hepatitis, carditis, interstitial nephritis, or interstitial pneumonitis. The cutaneous histological pattern shows a lymphocytic infiltrate, sometimes mimicking a cutaneous lymphoma, and the mortality rate is about 10%. When organ involvement exists, corticosteroids are often prescribed with dramatic improvement. Relapses may occur. (2) drug-induced pseudolymphoma which has a more insidious beginning with nodules and infiltrated plaques appearing several weeks after the beginning of the drug without constitutional symptoms. A pseudolymphoma pattern is seen on cutaneous histological slides. Complete improvement is usual after drug withdrawal, but a delayed lymphoma is possible. To decrease the ambiguity of the denomination of hypersensitivity syndrome, we propose the term of DRESS (Drug Rash with Eosinophilia and Systemic Symptoms).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9069593     DOI: 10.1016/s1085-5629(96)80038-1

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  173 in total

1.  DRESS syndrome.

Authors:  Ankush Gupta; Vijay Kumar Srivastava; Imran Rizvi; Atiya Aziz
Journal:  BMJ Case Rep       Date:  2012-07-03

2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Authors:  Sonal Choudhary; Michael McLeod; Daniele Torchia; Paolo Romanelli
Journal:  J Clin Aesthet Dermatol       Date:  2013-06

Review 3.  [Severe cutaneous adverse drug reactions. Clinical features and epidemiology ].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

4.  Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation.

Authors:  Elodie Descloux; Laurent Argaud; Jérôme Dumortier; Jean-Yves Scoazec; Olivier Boillot; Dominique Robert
Journal:  Intensive Care Med       Date:  2005-11-10       Impact factor: 17.440

5.  [DRESS syndrome after carbamazepine].

Authors:  G Wurpts; H Ott; A Schlüter; M Häusler
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

Review 6.  [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review].

Authors:  S Ständer; D Metze; T Luger; T Schwarz
Journal:  Hautarzt       Date:  2013-08       Impact factor: 0.751

7.  Cutaneous lymphoid hyperplasia mimicking cutaneous lymphoma in a hyperthyroid cat.

Authors:  Elisabeth Snead; Moira Kerr; Valerie Macdonald
Journal:  Can Vet J       Date:  2013-10       Impact factor: 1.008

8.  Drug rash with eosinophilia and systemic symptoms (DRESS) probably induced by cefotaxime: a report of two cases.

Authors:  Karim Aouam; Amel Chaabane; Adnen Toumi; Nadia Ben Fredj; Foued Ben Romdhane; Naceur A Boughattas; Mohamed Chakroun
Journal:  Clin Med Res       Date:  2011-08-04

9.  Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder: A Case Report.

Authors:  Katrin A Salva; Daniel Bennett; Jack Longley; Joan Guitart; Gary S Wood
Journal:  Am J Dermatopathol       Date:  2015-10       Impact factor: 1.533

10.  Enigma: infection or allergy? Vancomycin-induced DRESS syndrome with dialysis-dependent renal failure and cardiac arrest.

Authors:  Philip Simon Webb; Abdallah Al-Mohammad
Journal:  BMJ Case Rep       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.